We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CHEMM.CO

Price
671.00
Stock movement down
-15.50 (-2.26%)
Company name
ChemoMetec A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Devices
Markedsværdi
11.68B
Ent værdi
11.49B
Pris/omsætning
56.12
Pris/bog
17.34
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
177.66
Fremtidig P/E
52.29
PEG
-
EPS-vekst
25.80%
1 års afkast
32.74%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2025-12-16

UDBYTTE

CHEMM.CO betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E177.66
Pris til OCF88.27
Pris til FCF98.46
Pris til EBITDA125.43
EV i forhold til EBITDA123.42

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning56.12
Pris til egenkapital17.34
EV i forhold til salg55.22

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier17.40M
EPS (TTM)-
FCF pr. aktie (TTM)-

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)-
Bruttofortjeneste (TTM)-
Driftsindkomst (TTM)-
Nettoindkomst (TTM)-
EPS (TTM)-
EPS (1 år frem)12.83

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter341.85M
Nettotilgodehavender79.62M
Omsætningsaktiver i alt543.16M
Goodwill7.35M
Immaterielle aktiver145.69M
Ejendomme, anlæg og udstyr205.97M
Sum aktiver828.05M
Kreditor16.08M
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser146.99M
Sum gæld154.69M
Aktionærernes egenkapital673.36M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-
Investeringsudgifter (TTM)-
Fri pengestrøm (TTM)-
Udbetalt udbytte (TTM)-

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-
Afkast af aktiver-
Afkast af investeret kapital-
Kontant afkast af investeret kapital-

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning674.00
Daglig høj679.50
Daglig lav661.00
Daglig volumen33K
Højeste gennem alle tider1128.00
1 års analytiker estimat-
Beta1.59
EPS (TTM)-
Udbytte pr. aktie0.00
Ex-div dato15 Oct 2021
Næste dato for resultatpræsentation4 Feb 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
CHEMM.COS&P500
Nuværende prisfald fra top notering-40.51%-1.49%
Højeste prisfald-68.33%-19.00%
Højeste efterår dato11 Oct 20248 Apr 2025
Gennemsnitlig fald fra toppen-51.26%-2.63%
Gennemsnitlig tid til nyt højdepunkt-6 days
Maks. tid til nyt højdepunkt298 days89 days
OPLYSNINGER OM VIRKSOMHEDEN
CHEMM.CO (ChemoMetec A/S) company logo
Markedsværdi
11.68B
Markedsværdi kategori
Large-cap
Beskrivelse
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerod, Denmark.
Personale
170
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
ChemoMetec A/S recently reported first-quarter 2025 revenue exceeding forecasts alongside details of new product launches and a planned organizational restructuring. An important development is the co...
12. november 2025
ChemoMetec (CPSE:CHEMM) has been on investors’ watchlists with a sharp upswing in its share price in the past 3 months. The stock is up over 50% during this period and has caught the attention of the ...
11. november 2025
ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions r...
7. november 2025
Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 1...
6. november 2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive tren...
28. oktober 2025
ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At t...
9. oktober 2025
As the European markets navigate a complex landscape of interest rate policies and trade tensions, the pan-European STOXX Europe 600 Index has remained relatively stable, while major stock indexes in ...
2. oktober 2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating pro...
11. september 2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside i...
11. september 2025
As European markets experience a lift, buoyed by hopes of lower U.S. borrowing costs and a surge in business activity, investors are turning their attention to small-cap stocks that might offer unique...
29. august 2025
Næste side